ACUTE ARTERIAL OCCLUSION

Vascular Surgery Conference Michael Lebow, MD

ACUTE ARTERIAL OCCLUSION

"The operation was a success but the patient died"


- High Morbidity and Mortality
 - Emergent operations in high risk patients
 - 20% mortality reported (Dale, JVS 1984)
 - Endovascular approaches may lower peri-procedural mortality while preserving outcomes


Etiology of Arterial Occlusion

• Overview

- Atherosclerosis
- Thrombotic occlusion
- Embolic occlusion
- Treatment Options


Evolution of Atherosclerosis






- Areas of low wall shear stress
- Increased endothelial permeability
- Sub-endothelial lipid and macrophage accumulation
- Foam cells
- Formation of Fatty Streak
- Fibrin deposition and stabilizing fibrous cap

Evolution of Atherosclerosis






Necrosis

- Inflammatory environment
- Destabilization of fibrious cap

Evolution of Atherosclerosis



Rupture of Fibrous Cap

- Pro-thrombotic core
 Exposed to lumen
- Acute thrombosis
- Embolization of plaque materials and thrombus

Thromboembolism

- Embolus- greek "embolos" means projectile
- Mortality of 10-25%
- Mean age increasing 70 years
 - Rhumatic disease to atherosclerotic disease
- Classified by size or content
 - Macroemboli and microemboli
 - Thrombus, fibrinoplatelet clumps, cholesterol

Macroemboli






Cardiac Emboli

- Heart source 80-90% of thrombus macroemboli
- MI, A.fib, Mitral valve, Valvular prosthesis
- Multiple emboli 10% cases
- TEE
 - Views left atrial appendage, valves, aortic root
 - not highly sensitive

Thromboembolism



• 75% of emboli involve axial limb vasculature

- Femoral and Polilteal
 - ->50% of emboli
- Branch sites
- Areas of stenosis

Thromboembolism

Non-cardiac sources

- Aneurysmal (popliteal > abdominal)
- Paradoxical
 - Follows PE with PFO
- TOS
- Cryptogenic –5-10%
- Atheroemboli (artery to artery)

- Shaggy Aorta
 - Thoracic or abdominal
- Spontaneous
- Iatrogenic
 - 45% of all atheroemboli
- "Blue toe syndrome"
 - Sudden
 - Painful
 - cyanotic
 - palpable pulses
- livedo reticularis




Copyright ©2005, 2000, 1995, 1989, 1976 by Elsevier, Inc.

- Risk factors: PVD, HTN, elderly, CAD, recent arterial manipulation
- Emboli consist of thrombus, platelet fibrin material or cholesterol crystals
- Lodge in arteries 100 –200 micron diameter



- Affect variety of end organs
 - extremities, pelvis ,GI, kidney, brain
- Work-up:
 - TEE ascending aorta, CT Angio, Angiography
- Laboratory: CRP elevated, eosinophilia
- Warfarin my destablize fibrin cap and trigger emboli.



- Reported incidence of 0.5-1.5% following catherter manipulation
 - Advance/remove catheters over guidewire
 - Brachial access? controversial
- Limited Sx– Anti-coagulation/ observation
- Temporal delay up to 8 weeks before renal symptoms

Therapy

- Prevention and supportive care
 - Statins, prostacyclin analogs (iloprost), ASA, Plavix
- Elimination of embolic source and reestablishing blood flow to heal lesions
- Surgical options: endaterectomy or resection and graft placement
 - Abdominal Aorta Aorta-bi-fem bypass
 - Ligation of external iliac and extra-anatomic bypass if high risk
- Endovascular therapy
 - Angioplasty & stenting higher rate of recurrence
 - Athrectomy no data

Acute Thrombosis

- Graft thrombosis (80%)
 - intimal hyperlasia at distal anastamosis (prosthetic)
 - Retained valve cusp
 - Stenosis at previous site of injury

Native artery

- Intra-plaque hemmorhage
- Hypovolemia
- Cardiac failure
- hypercoagable state
- Trauma
- Arteritis, popliteal entrapment, adventitial cystic disease

Acute Thrombosis

Heparin Induced Thrombosis

- White Clot Syndrome
- Heparin dependent IgG anti-body against platelet factor 4
- 3-10 days following heparin contact
- Dx: thrombosis with > 50% decrease in Platelet count
- Tx: Direct throbin inhibiors: Agartroban & Hirudin

 Avoid all heparin products
- Morbity and Mortality: 7.4-61% and 1.1-23%

Other causes of Thrombosis

- Anti-thrombin III Defiency
- Protein C & S Defiency
- Factor V Leiden
- Prothrombin 20210 Polymorphism
- Hyper-homocystinemia
- Lupus Anti-coagulant (anti phospho-lipid syndrome)

"The Cold Leg"

- Clinical Diagnosis
 - Avoid Delay
 - Anti-coagulate immediately
 - Pulse exam
 - 6 P's (pain, pallor, pulselessness, parathesias, paralysis, poiklothermia)
- Acute –vs- Acute on chronic
 - Collateral circulation preserves tissue
 - Traditional 4-6 hr rule may not apply

Diagnostic Evaluation

SVS/ISCVS Classification

- "Rutherford Criteria"
- Class I: Viable
 - Pain, No paralysis or sensory loss
- Class 2: Threatened but salvageable
 - 2A: some sensory loss, No paralysis >No immediate threat
 - 2B: Sensory and Motor loss > needs immediate treatment
- Class 3: Non-viable
 - Profound neurologic deficit, absent capillary flow,skin marbling, absent arterial& venous signal


Therapeutic Options


– Class 1 or 2A

- Anti-coagulation, angiography and elective revascularzation
- Class 2B
 - Early angiographic evaluation and intervention
 - Exception: suspected common femoral emboli
- Class3
 - Amputation

Diagnostic Evaluation

- Modalities
 - Non-invasive:
 - Segmental pressure drop of 30mmhg
 - Waveforms
 - CTA / MRA : avoid nephrotoxity
 - Center dependent
 - Wave of the future?
 - Contrast Angiography
 - Gold Standard







Thrombotic –vs- Embolic

• Thrombotic

- History
 - Claudication, PVD
 - Bypass graft
- Physical
 - Hair loss, shiny skin
 - Bi-lateral Dz
- Angiographic
 - Diffuse disease
 - mid vessel occlusion
- PVD confuses diagnosis

• Embolic

- History
 - Cardiac events
 - Acute onset
 - Hx of emboli
- Physical
 - Normal contralateral exam
 - A.fib
- Angiographic
 - meniscus Cut-off in normal vessel
 - Bifurcations affected

Determination of etiology possible in 85% of cases

Treatment Options

• Multiple options available

- Conventional surgery
 - embolectomy
 - endarterectomy
 - revascularization
- Thrombolytic therapy
- Percutanious mechanical thrombectomy
- Native vessel thrombosis often require more elaborate operations

Treatment Fundamentals

- Early recognition and anti-coagulation
 - Minimizes distal propagation and recurrent emboli
- Modality of Tx depends on:
 - Presumed etiology
 - Location/morphology of lesion
 - Viability of extremity
 - Physiologic state of patient
 - Available vein conduit for bypass grafting

Treatment : Thrombosis

Separate graft thrombosis into early and Late groups

Early thrombosis

- Technical defect
- Repairable
- Avoid lytic Tx
 - 14 days vein
 - 30 days graft
- Explore both anastamosis
- On-table Angio
 - Twists, kniks, stenosis

Late thrombosis

- Duration & degree of ischemia
- Lytic Thearpy (clas1-2a)
 - Good 1st approach
 - Unmasks lesion (valve/stenosis)
 - F/u endo or open repair
- Open surgery (2b)
 - Thrombectomy/patch
 - Re-bypass

- Fogarty embolectomy catheter
 - Intoduced 1961
- Adherent clot catheter
- Graft thrombectomy catheter
- Thru-lumen catheter
 - Selective placement over wire
 - Administer: lytics, contrast





Surgical Therapy

- Iliac and femoral embolectomy
 - Common femoral approach
 - Transverse arteriotomy proximal profunda origin
 - Collateral circulation may increase backbleeding



– Examine thrombus

- Popliteal embolectomy
 - 49% success rate from femoral approach
 - Blind passage selects peroneal 90%
 - may expose tibialperoneal trunk & guide catheter
 - Idrectly cannulate distal vessels

- Distal embolectomy
 - Retrograde/antegrade
 via ankle incisions
 - Frequent Rethrombosis
 - Thrombolytic Tx viable alternative

- Completion angiography
 - 35% incdence of retained thrombus
 - IVUS more sensitive then angio
- Failure requires
 - Thrombolytic thearpy
 - revascularization

Thrombolytic Therapy

Advantages

- Opens collaterals & microcirculation
- Avoids sudden reperfusion
- Reveals underlying stenosis
- Prevent endothelial damage from balloons

Risks

- Hemmorhage
- Stroke
- Renal failure
- Distal emboli transiently worsen ischemia

Surgery –vs- Thrombolysis

- STILE Trial
- Surgery vs Thrombolytics for Ischemia of Lower Extremity
 - 393 pts with non-embolic occlusion
 - Surgery vs r-TPA or r-UK
- Thrombolytics : improved amputation free survival and shorter hospital stay (0-14 days)
- Surgery: revascularization more effective for ischemia of > 14 days duration

Ann Surg 1994, 220:251

Surgery –vs- Thrombolysis

TOPAS Trial

- 2 phase
- 544 patients
- r-UK vs Surgery
- Need for surgery Reduced 55%
- Similar amputation and mortality rates

NEJM 338, 4/16/98





Indications for Thrombolysis

Category 1-2a limbs should be considered

- Class 2b : Two schools of thought

1)"Delay in definitive Tx"

2)"Thrombolytics extend window of opportunity"

• Clots <14days most responsive

- But even chronic thrombus can be lysed

- Large clot burden
 - Better response to lytic tx than surgery
 - Requires longer duration of thrombolytics

Technique of Thrombolysis

- Guide Wire Traversal Test (GTT)
 - Abilty to traverse lesion best predictor of success
 - Use 0.035 in angled glide wire
 - "knuckling-over" indicates sub-intimal plane
 - Attempt pro-grade, Anti-grade, lytic bolus

Technique of Thrombolysis

- Catheter directed delivery
 - 1) Lace clot via catheter with side holes
 - 2) Pulse-Spray technique (mechanical component)
- Urokinase and TPA equally effective
- 4 hr treatment followed by angiogram
 - 4000IU/min x4hr, 2000Iu/M=min x 48h
 - r-UK (TOPAS Trial)
 - no improvement after 4hr >> surgery
- Continue Heparin gtt
- Fibrinogen levels

Mechanical Thrombectomy

- Percutaneous aspiration embolectomy
 - Viable alternative in selected patents
 - Varity of devises
 - Combines diagnostic and therapeutic procedure
 - Removes non-lysable debris
 - Effective in distal vessels
 - Risk distal embolization
 - Combine with lytic Tx

Reperfusion Syndrome

- Ischemic-reperfusion syndrome
 - Local: endothelial damage, capillary permeability, Transudative swelling, cellular damage
 - Compartment Syndrome
 - Tx: Fasciotomy
 - Systemic: Lactic Acidosis, Hyperkalemia, Myoglobin, Inflammatory Cytokines
 - Cardiopulmonary complications
 - Renal Tubular necrosis
 - Myoglobin precipitates
 - Tx: Volume, Urinary alklinization

Summary

- Thrombotic and embolic occlusions are separate processes with different presentations and treatments
- Treatment pathways in AAO are complex and vary depending on clinical situation
- Catheter-based treatments preserve outcomes with less overall morbidity